Theralase Technologies Inc (FRA:TTX)

Q3 2024 Theralase Technologies Inc Earnings Call Transcript

Dec 4, 2024 / 04:00 PM GMT

Release Date Price: €0.137 (-4.20%)

Transcript

Key Points

Positve

Theralase Technologies Inc (TLTFF) has demonstrated strong clinical data in their phase two bladder cancer study, with a 61.9% complete response rate and a 43.6% duration of response at 450 days.
The company has successfully reduced its net loss by 7% year over year, primarily due to decreased spending on research and development expenses.
Theralase Technologies Inc (TLTFF) has raised approximately $3.9 million through private placements, strengthening its financial position.
The company plans to expand its clinical study sites and increase patient enrollment, which could accelerate the completion of its phase two bladder cancer study.
Theralase Technologies Inc (TLTFF) is exploring new indications for its technology, including brain, lung, and blood cancers, which could significantly expand its market potential.

Negative

Theralase Technologies Inc (TLTFF) experienced a 12% decrease in total revenue for the nine-month period ended September 30, 2024, compared to the same period in 2023.
The company's gross margin decreased from 49% to 47% year over year, attributed to an increase in material costs.
Selling expenses increased by 33%, primarily due to higher spending on sales salaries and advertising.
The company faces significant costs, estimated between $15 million and $30 million, to complete its phase two bladder cancer clinical study.
Theralase Technologies Inc (TLTFF) has not yet secured breakthrough therapy designation (BTD) from the FDA, which could delay potential regulatory approvals.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TLT.V - Theralase Technologies Inc
Q3 2024 Theralase Technologies Inc Earnings Call
Dec 04, 2024 / 04:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everyone. My name is Matthew Perten and I'll be hosting thela Technology Inc quarterly investor conference call. Today.

The focus of today's call will be a presentation and discussion of the company's third quarter, 2024 interim financial statements and an update on the phase two bladder cancer clinical study.

Following each presentation, there will be a question and answer session. The agenda for today's call. Firstly, Christina Hatchie, Chief Financial Officer will present the third quarter, interim financial statements followed by a Q&A session the results afterwards. Roger Duan White President and CEO will provide an update on the phase two bladder cancer clinical study which will also

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.